Common painkiller may boost Chemo's power against cancer
NCT ID NCT01719926
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether adding indomethacin, a common anti-inflammatory drug, to standard platinum-based chemotherapy is safe for people with colorectal, esophageal, or ovarian cancers. The 13 participants received escalating doses of indomethacin alongside their chemo. The main goal was to find safe dosing levels and watch for side effects, not to measure effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Indomethacin (a COX inhibitor, similar to ibuprofen) combined with platinum-based chemotherapy
What this could lead to
If successful, this could point toward a way to make chemotherapy more effective by blocking resistance signals from stem cells.
What could go wrong
This is a very early, small Phase 1 trial with only 13 participants. It only tests safety and dosing, not whether it actually works. Indomethacin can cause stomach bleeding or kidney issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Meander Medisch Centrum
Amersfoort, Utrecht, 3813TZ, Netherlands
-
Oncology Institute of Southern Switzerland
Bellinzona, CH-6500, Switzerland
-
UMC Utrecht
Utrecht, Utrecht, 3584CX, Netherlands
-
the Netherlands Cancer Institute
Amsterdam, Amsterdam, 1066 CX, Netherlands